175 related articles for article (PubMed ID: 16052529)
1. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
Dell K; Koesters R; Gissmann L
Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
3. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
[TBL] [Abstract][Full Text] [Related]
4. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
5. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
6. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.
Klimuk SK; Najar HM; Semple SC; Aslanian S; Dutz JP
J Invest Dermatol; 2004 Apr; 122(4):1042-9. PubMed ID: 15102096
[TBL] [Abstract][Full Text] [Related]
7. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
8. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
[TBL] [Abstract][Full Text] [Related]
11. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
12. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides.
Daftarian PM; Mansour M; Pohajdak B; Fuentes-Ortega A; Korets-Smith E; Macdonald L; Weir G; Brown RG; Kast WM
J Transl Med; 2007 Jun; 5():26. PubMed ID: 17555571
[TBL] [Abstract][Full Text] [Related]
13. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.
Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470
[TBL] [Abstract][Full Text] [Related]
15. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
16. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses.
Speidel K; Osen W; Faath S; Hilgert I; Obst R; Braspenning J; Momburg F; Hämmerling GJ; Rammensee HG
Eur J Immunol; 1997 Sep; 27(9):2391-9. PubMed ID: 9341785
[TBL] [Abstract][Full Text] [Related]
17. Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice.
Tindle RW; Herd K; Londoño P; Fernando GJ; Chatfield SN; Malcolm K; Dougan G
Virology; 1994 May; 200(2):547-57. PubMed ID: 7513919
[TBL] [Abstract][Full Text] [Related]
18. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour.
Doan T; Herd K; Ramshaw I; Thomson S; Tindle RW
Cancer Immunol Immunother; 2005 Feb; 54(2):157-71. PubMed ID: 15480657
[TBL] [Abstract][Full Text] [Related]
19. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
20. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]